Clinical and cost-effectiveness of screening newborns for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry.
Contributors: Tran, Khai.; Canadian Coordinating Office for Health Technology Assessment
Series: Technology overview -- no. 19; Technology overview (Ottawa, Ont. : 1998) -- issue 19.
Publisher: Canadian Coordinating Office for Health Technology Assessment
Published: 2006
Place of publication: Ottawa
Language: eng
Number of pages: 10
Subjects: Metabolic disorders in children -- Molecular diagnosis -- Evaluation.; Metabolic disorders in children -- Molecular diagnosis -- Cost effectiveness.; Fatty acids -- Metabolism -- Disorders -- Molecular diasnosis.; Fatty acids -- Metabolism -- Disorders -- Molecular diasnosis -- Cost effectiveness.; Genetic disorders in children -- Molecular diagnosis -- Evaluation.; Genetic disorders in children -- Molecular diagnosis -- Cost effectiveness.; Mass spectrometry -- Therapeutic use -- Cost effectiveness.; Newborn infants -- Diseases -- Molecular diagnosis -- Evaluation.; Newborn infants -- Diseases -- Molecular diagnosis -- Cost effectiveness.; Medical screening -- Canada -- Evaluation.
Other titles: Newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry
Notes: "March 2006".

"This Overview is based on the Technology Report commissioned by CCOHTA: Tran, K. [et al.] Newborn screening for medium chain acylk-CoA dehydrogenase deficiency using tandem mass spectrometry: clinical and cost-effectiveness [Technology report no 62]. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2006."

Includes bibliographical references (p. 10).